On Nov. 15, 2018, Pascal Biosciences announced the peer reviewed publication of their licensed cannabinoid-derived drug program for glioblastoma in the European Journal of Medicinal Chemistry, a peer reviewed journal.

This work detailed the discovery of compounds based on cannabinoids, and followed their chemical optimization into potent tumor killing agents.